Antibody-drug conjugates (ADCs) are a new class of highly potent biopharmaceutical drugs designed as a targeted therapy for the treatment of patients with cancers. Typically, an ADC is composed of three core elements, the monoclonal antibody, the linker and the cytotoxic agent. In developing ADCs, an anticancer drug is coupled to an antibody that specifically targets a certain tumor marker (e.g. a protein that, ideally, is only to be found in or on tumor cells). Antibodies track these proteins down in the body and attach themselves to the surface of cancer cells. The biochemical reaction between the antibody and the target protein (antigen) triggers a signal in the tumor cell, which then absorbs or internalizes the antibody together with the cytotoxin. After the ADC is internalized, the cytotoxic drug is released and kills the cancer. Typical examples are Brentuximab vedotin (SGN35), Trastuzumab-emtansine (T-DM1), Inotuzumab ozogamicin (CMC-544) and Gemtuzumab ozogamicin.
Creative Biolabs' scientists are focusing on applying excellent science and technology to discover and develop potential new ADCs with the goal of becoming first-in-class therapeutics. We also provide custom ADCs design and construction services. Besides expression and purification of ADCs, we also provide pharmacokinetics studies, HPLC/ELISA/TFC-MS/MS analysis for free drug and pharmacokinetics analysis.
ADC Name | Cytotoxin | Linker | MAb | Target |
ABT-414-VC-MMAE | Auristatin MMAE | Valine–citrulline | ABT-414 | EGFR |
AGS-16M8F-VC-MMAE | Auristatin MMAF | Valine–citrulline | AGS-16M8F | AGS-16 |
AMG-172-SMCC-DM1 | Maytansine DM1 | SMCC | AMG-172 | CD70 (CD27L) |
AMG-595-SMCC-DM1 | Maytansine DM1 | SMCC | AMG-595 | EGFRviii |
ARX788 | Amberstatin (AS269) | Valine–citrulline | ARX788 | HER2 |
ASG-15ME-VC-MMAE | Auristatin MMAE | Valine–citrulline | ASG-15ME | SLTRK6 |
ASG-22CE-VC-MMAE | Auristatin MMAE | Valine–citrulline | ASG-22CE | Nectin 4 |
ASG-22ME-VC-MMAE | Auristatin MMAE | Valine–citrulline | ASG-22ME | Nectin 4 |
ASG-5ME-VC-MMAE | Auristatin MMAE | Valine–citrulline | ASG-5ME | SLC44A4 (AGS-5) |
BAY-79-4620-VC-MMAE | Auristatin MMAE | Valine–citrulline | BAY-79-4620 | CA-IX |
BAY-94-9343-SPDB-DM4 | Maytansine DM4 | SPDB | BAY-94-9343 | Mesothelin |
Brentuximab-VC-MMAE | Auristatin MMAE | Valine-citrulline | Brentuximab vedotin (SGN35) | CD30 |
BT-062-SPP-DM4 | Maytansine DM4 | SPP | BT-062 | CD138 |
Coltuximab-SPDB-DM4 | Maytansine DM4 | SPDB | Coltuximab Ravtansine (SAR-3419) | CD19 |
EC-mAb-Maleimidocaproyl Phenylalanine-PBD dimer | Pyrrolobenzodiazepine (PBD) dimer | Maleimidocaproyl Phenylalanine | SGN- CD33A (EC-mAb) | CD22 |
Epratuzumab–Lysine-SN38 | Irinotecan metabolite (SN38) | Lysine | Epratuzumab–SN-38 | CD33 and CD22 |
Gemtuzumab-Hydrazone-N-acetyl- γ Calicheamicin | N-acetyl- γ Calicheamicin | Hydrazone | Gemtuzumab ozogamicin | GPNMB (Glycoprotein NMB) |
Glembatumumab-VC-MMAE | Auristatin MMAE | Valine–citrulline | Glembatumumab vedotin (CDX-011) | Tissue Factor (TF) |
HuMax-TF-VC-MMAE | Auristatin MMAE | Valine–citrulline | HuMax-TF-ADC | CD37 |
IMGN-529-SPDB-DM4 | Maytansine DM4 | SPDB | IMGN-529 | Folate receptor 1 |
IMGN-853-Lysine-SN38 | Irinotecan metabolite (SN38) | Lysine | IMGN-853 | TACSTD2 / TROP2 or EGP1 |
Inotuzumab-Hydrazone-N-acetyl- γ Calicheamicin | N-acetyl- γ Calicheamicin | Hydrazone (4-(4-acetylphenoxy)butanoic acid) | Inotuzumab ozogamicin (CMC-544) | CEA-CAM4/CD66e |
Labetuzumab-Carbonate-SN38 | Irinotecan metabolite (SN38) | Carbonate | Labetuzumab-SN-38 (IMMU-130) | CD56 |
Lorvotuzumab-N-succinimidyl-4-(2-pyridyldithio)butyrate-DM1 | Maytansine DM1 | (N-succinimidyl-4-(2-pyridyldithio)butyrate) | Lorvotuzumab mertansine (IMGN-901) | CD70 (TNFSF7) |
MDX-1203-Di-peptide-Duocarmycin | Duocarmycin (DNA damage) | Di-peptide | MDX-1203 | STEAP1 |
Milatuzumab doxorubicin (IMMU-110) | Doxorubicin | Hydrazone | Milatuzumab doxorubicin (IMMU-110) | Mucin 16 |
MLN-0264-VC-MMAE | Auristatin MMAE | Valine–citrulline | MLN-0264 | CD79b |
PF-0626350-VC-MMAE | Auristatin MMAE | Valine–citrulline | PF-0626350 | |
Pinatuzumab-VC-MMAE | Auristatin MMAE | Valine–citrulline | Pinatuzumab vedotin (RG-7593 / DCDT 2980S) | NaPi2b |
PSMA-ADC-SPDB-DM4 | Maytansine DM4 | SPDB | PSMA-ADC | |
RG-7450-VC-MMAE | Auristatin MMAE | Valine–citrulline | RG-7450 / DSTP 3086 S | Endothelin receptor ETB |
RG-7458-SMCC-DM1 | Maytansine DM1 | SMCC | RG-7458 / DMUC 5754 A | CA6 |
RG-7596-VC-MMAE | Auristatin MMAE | Valine–citrulline | RG-7596 / DCDS4501A | |
RG-7599-VC-MMAE | Auristatin MMAE | Valine–citrulline | RG-7599 / DNIB 0600 A | CD70 |
RG-7600-VC-MMAE | Auristatin MMAE | Valine–citrulline | RG-7600 | CD70 |
RG-7636-VC-MMAE | Auristatin MMAE | Valine–citrulline | RG-7636 | CD19 |
SAR-566658-SPDB-DM4 | Maytansine DM4 | SPDB | SAR-566658 | LIV1 |
SC16LD6.5-Di-peptide-DNA damaging agent | DNA damaging agent | Di-peptide | SC16LD6.5 | HER2 |
SGN-75-VC-MMAE | Auristatin MMAF | Valine–citrulline | SGN-75 | CD70 |
SGN-CD19A-VC-MMAE | Auristatin MMAE | Valine–citrulline | SGN-CD19A | |
SGN-LIV1-A-VC-MMAE | Auristatin MMAE | Valine–citrulline | SGN-LIV1-A | |
SGN-Maleimidocaproyl Phenylalanine-PBD dimer | Pyrrolobenzodiazepine (PBD) dimer | Maleimidocaproyl Phenylalanine | SGN CD70 A | |
Trastuzumab-SMCC-DM1 | Maytansine DM1 | SMCC | Trastuzumab-emtansine (T-DM1) | |
Vorsetuzumab-VC-MMAE | Auristatin MMAF | Valine–citrulline | Vorsetuzumab mafodotin |
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.